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ABSTRACT  
 
Tuberculosis, caused by Mycobacterium tuberculosis, remains one of the main threats to 
mankind. Despite the intense research on the immune response to tuberculosis, major questions 
remain unsolved, one of which relates to the fact that the efficacy of the current vaccine, 
Mycobacterium Bovis BCG, is variable. However, no other experimental vaccines against tuberculosis 
developed in the last 100 years were proven to be better than BCG. Therefore BCG remains the only 
vaccine available to date to prevent tuberculosis. A possible explanation for the variability of BCG 
efficacy relies on the fact that the immune response triggered by BCG and M. tuberculosis is 
different. Nevertheless, M. tuberculosis-based experimental vaccines tend not to protect better than 
BCG. We therefore hypothesized that the basic protective response triggered by BCG must be 
appropriate, although it needs to be improved in order to confer higher and longer lasting protection. 
In this work, we performed a comparative study of M. tuberculosis versus BCG infection on 
dendritic cells (DCs) and macrophages to better understand how these pathogens interact with cells 
of the innate immune system and how that might translate into an effective, or not, T helper (Th) cell 
response. We found that macrophages and DCs respond differently to M. tuberculosis or BCG 
stimulation in what concerns cytokine expression. The expression of IL-12p40, TNF and IL-6 is 
significantly higher in DCs than in macrophages stimulated with either mycobacteria. Nevertheless, 
the expression of IL-12p35 and IL-10 was similar in both cell types. We also found that the same cell 
type respond differently to M. tuberculosis or BCG. M. tuberculosis-stimulated DCs induced higher 
levels of p40 and p19 monomers and of the bioactive cytokines IL-12 and IL-23, respectively. BCG-
stimulated DCs produced higher amounts of TNF. The amounts of IL-6 and IL-10 secreted upon 
stimulation of DCs with M. tuberculosis or BCG were similar. The differential expression of IL-12 and 
IL-23 might be correlated in part to a higher activation of the MAP kinase ERK1/2 in DCs in response 
to M. tuberculosis than to BCG. Although macrophages were in general poorly induced to produce 
cytokines, when compared to DCs, the threshold of ERK1/2 activation was higher in stimulated 
macrophages. A consequence of the differential activation of DCs was reflected on the distinct type of 
Th responses developed when M. tuberculosis- or BCG-infected DCs presented OVA peptide to TCR-
transgenic CD4+ T cells. M. tuberculosis-infected DCs were able to induce the development of both 
Th1 and Th17 responses, whereas BCG-infected DCs presented a shift towards Th17 responses. 
These differences are of interest considering the importance of Th1/Th17 balance during vaccination. 
Further understanding the molecular mechanisms dictating this differential Th response will be used 
for the development of new vaccines.  
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RESUMO 
 
A tuberculose é causada pelo Mycobacterium tuberculosis e constitui um grave problema a 
nível mundial. Apesar de todo o esforço dedicado ao estudo desta infecção, questões como a 
variabilidade da eficácia da corrente vacina em uso, M. bovis BCG, permanecem inexplicáveis. No 
entanto, nos últimos 100 anos, não foi experimentalmente desenhada outra vacina mais eficiente do 
que o BCG. Sendo assim, a única vacina disponível até ao momento para combater a tuberculose é o 
BCG. Uma possivel explicação para a variabilidade da vacina consiste no facto de o M. tuberculosis e 
o M. bovis BCG desencadearem uma resposta imunológica diferente.Contudo, vacinas experimentais 
baseadas no M. tuberculosis não conferem maior protecção do que o BCG. A nossa hipótese, é que 
a resposta desencadeada pelo BCG deve ser adequada, embora necessite de ser melhorada de 
modo a conferir uma protecção maior e mais prolongada.  
Neste trabalho foram comparadas as infecções por M. tuberculosis versus BCG em células 
dendríticas (DCs) e em macrófagos, com os objectivos de compreender melhor a interacção entre 
estes agentes patogénicos e o sistema imunológico inato, e como é que isso se traduz, ou não, 
numa reposta T de ajuda (Th) eficaz. Os nossos resultados mostram que as respostas induzidas 
pelos macrófagos e pelas DCs estimulados por M. tuberculosis ou por BCG, em termos de expressão 
de citocinas, são diferentes. A expressão de IL-12p40, TNF e IL-6 induzida por ambas as 
micobactérias foi significativamente maior em DCs do que em macrófagos. Contudo, a expressão de 
IL-12p35 e IL-10 foi semelhante em ambos os tipos celulares. Observamos, também, que o mesmo 
tipo celular responde de modo diferente ao M. tuberculosis ou ao BCG. As DCs estimuladas pelo M. 
tuberculosis induziram níveis elevados de p40 e p19, bem como das respectivas citocinas bioactivas 
IL-12 e IL-23. As DCs estimuladas pelo BCG produziram elevados níveis de TNF. A produção de IL-6 
e IL-10 foi semelhante quer nas DCs estimuladas pelo M. tuberculosis quer pelo BCG. A expressão 
diferencial de IL-12 e de IL-23 poderá estar correlacionada, em parte, com uma maior activação da 
MAP cinase ERK1/2 pelas DCs em resposta ao M. tuberculosis relactivamente ao BCG. Embora a 
indução de citocinas pelos macrófagos fosse menor do que pelas DCs, o threshold de activação do 
ERK1/2 induzido pelos macrófagos foi maior. A diferente activação induzida pelo M. tuberculosis ou 
BCG em DCs reflectiu-se no tipo de resposta Th diferenciada. Em DCs estimuladas com M. 
tuberculosis ou BCG, que apresentam o péptido OVA a células T CD4+  cujo TCR é transgénico, 
observamos que as DCs estimuladas com M. tuberculosis induziram o desenvolvimento de respostas 
Th1 e Th17, enquanto que DCs estimuladas com BCG induziram uma resposta Th17 superior à 
observada com M. tuberculosis. Considerando a importância do balanço Th1/Th17 durante a 
   xiii 
vaccinação, as diferenças observadas são de extrema relevância, dado que a compreensão dos 
mecanismos moleculares que ditam esta resposta diferencial consiste numa estratégia para o 
desenvolvimento de novas vacinas contra a tuberculose. 
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I. INTRODUCTION 
 
1.1. EPIDEMIOLOGY  
In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global 
emergency. Since then, TB remains one of the main threats to mankind. Nowadays, TB is the 
world’s second commonest cause of mortality and morbidity from infectious diseases, despite 
the improvements in the health care services and all the efforts devoted to the understanding of 
this disease in the last decades (Corbett et al., 2003). 
The WHO has estimated that one-third of the world’s population (2 billion people) is 
infected with Mycobacterium tuberculosis, the etiologic agent of TB. Of these, 1 in 10 people will 
become sick with active TB in their lifetime. The latest estimates of the global burden of TB show 
that there were 9.27 million new cases of TB in 2007 (including 1.37 million cases among 
human immunodeficiency virus (HIV)-positive people). There were also approximately 0.5 million 
new cases of multidrugresistent-TB (MDR-TB), of which around 0.3 million were among people 
not previously treated for TB. South-East Asia and Western Pacific regions account for 55% of 
global cases and the African Region for 31%; the other three regions (the Americas, European 
and Eastern Mediterranean regions) account for small fractions of the global cases. Among the 
15 countries with the highest estimated TB incidence rates, 13 are in Africa, a phenomenon 
linked to high rates of HIV coinfection (WHO, 2009). The estimates of cases and deaths in HIV-
positive individuals in 2007, as well as in previous years are substantially higher than those 
published previously by WHO (1.32 million deaths from TB in HIV-negative people with an 
additional 0.46 million TB deaths in HIV-positive people) (WHO, 2009).  
Regarding the incidence rate of TB in Western Europe, the situation in Portugal is 
considered one of the most severe (DGS, 2006; EuroTB, 2006). Nearly 3 000 of new cases of all 
forms of TB were notified in 2007, being 20% of all TB cases in HIV-positive people, and 0.9% of 
all new cases MDR-TB (Hollo et al., 2009; WHO, 2009). 
Collectively, these statistics show that TB remains a major global health problem and that 
there is an urgent need for more effective control and prophylactic resources to fight TB 
worldwide. 
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1.2. PREVENTION AND THERAPY OF TUBERCULOSIS 
Mycobacterium bovis BCG is the only vaccine currently available against TB. BCG is an 
attenuated strain of M. bovis (the etiological agent of cattle TB), derived from a virulent strain at 
the start of the last century, after more than 13 years of continuous in vitro passage (Andersen 
and Doherty, 2005). After almost a century from its discovery and more than 3 billion 
administrations, BCG is still in use today (Fine, 1995). However, BCG vaccination did not match 
all the expectations it evoked, because although it prevents disseminated TB in newborns (Colditz 
et al., 1995; Lanckriet et al., 1995; Murhekar et al., 1995; Trunz et al., 2006; Zodpey et al., 
2005; Zodpey et al., 1998) its protection against the most common form of the disease, 
pulmonary TB in adults, can range anywhere from below zero to over 80% (Fine, 1995; 
Kaufmann, 2000; Sterne et al., 1998). This difference in protection is not well understood, 
however some aspects might account for it, such as the interference with the immune response 
to BCG vaccination by previous exposure to environmental mycobacteria (Brandt et al., 2002; 
Demangel et al., 2005; Roche et al., 1995); differences in BCG sub-strains (Behr, 2001a, b; 
Fine, 1995; Fine et al., 1994); deletion of protective antigens from BCG; failure of BCG to 
stimulate adequate immunity (Aagaard et al., 2009); differences in the route of administration 
(Skeiky and Sadoff, 2006), age of administration (Skeiky and Sadoff, 2006). Furthermore, the 
protection afforded by BCG is not life-long lasting, and it is believed that BCG is protective for only 
10-20 years, which implies that protection wanes just as the risk of getting pulmonary TB 
increases (Sterne et al., 1998). The need to develop a new vaccine against TB is urgent and 
efforts are being made to do so. The most promising strategies for the generation of vaccine 
candidates are subunit protein vaccines, attenuated live vaccines or the combination of both. 
While attenuated live vaccines provide prolonged exposure of the host immune system to newly 
synthesized antigens, the advantage of subunit vaccines is the possibility that their efficacy may 
not be compromised by exposure to environmental mycobacteria or by prior BCG vaccination 
(Andersen, 2007; Andersen and Doherty, 2005). 
Although it is clear that BCG is limited to confer protection against TB, the search for a 
better vaccine has so far failed. The efforts underlying the search of a new vaccine against TB 
should perhaps not only focus on the understanding of M. tuberculosis infection, but also on the 
understanding of BCG immunobiology, the way it activates innate immunity and further induces T 
cell responses. Additionally, the way that M. tuberculosis and BCG interfere with the host 
immunity should be a target of investigation and an issue to be taken into account in the 
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development of a new vaccine against TB. Therefore, a comprehensive analysis of the interaction 
of both M. tuberculosis and BCG with the immune system is important and pertinent. 
 
1.3. Mycobacterium tuberculosis COMPLEX - M. tuberculosis AND M. bovis BCG 
FEATURES 
TB, in humans and in animals, results from exposure to bacilli within the M. tuberculosis 
complex (i.e., Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, 
Mycobacterium pinnipedi, Mycobacterium microti, Mycobacterium caprae, or Mycobacterium 
canettii (Cousins et al., 2003). Mycobacteria from M. tuberculosis complex share more than 99% 
homology for some loci (Brosch et al., 2002; Mostowy and Behr, 2005; Smith et al., 2006). The 
Mycobacterium genus comprises several bacteria, including non-pathogenic environmental 
mycobacteria (Dormans et al., 2004; Kremer et al., 1998; Mostrom et al., 2002; van Soolingen 
et al., 1998); but also virulent mycobacteria, in addition to M. tuberculosis, such as M. leprae 
and M. ulcerans, the causative agents of leprosy and Buruli ulcer, respectively (Debacker et al., 
2004; WHO, 2000). Another pathogenic mycobacteria is M. avium, although it only causes 
disease in immunocompromised individuals, such as HIV-positive patients (Pozniak, 2002; 
Primm et al., 2004). M. tuberculosis and M. bovis cause a similar course of infection and 
pathology in humans (Cosma et al., 2003). Although M. tuberculosis has no natural reservoir 
outside humans, several TB experimental animal models exist (Boshoff and Barry, 2005; Cosma 
et al., 2003; Flynn, 2006; Kaufmann, 2003; North and Jung, 2004; Young, 2009). In contrast, 
M. bovis has a broad range of natural hosts, from humans to cattle (O'Reilly and Daborn, 1995). 
Mycobacteria share a characteristic cell wall, composed by mycolic acids, that makes up more 
than 50% of its dry weight. The lipid content of this cell wall enables the retention of basic dyes in 
the presence of acid alcohol, a hallmark characteristic of mycobacteria (Brennan, 2003; Cosma 
et al., 2003; Kaufmann, 2006). 
The genome of M. tuberculosis has been sequenced and is 4.41 Mb in size. It contains 
near 4000 protein-coding genes of which 52% have known function (Cole et al., 1998). Only 376 
putative proteins share no homology with known proteins and presumably are unique to M. 
tuberculosis (Camus et al., 2002; North and Jung, 2004).  
Whole genome DNA microarray techniques have identified 129 M. tuberculosis specific 
open reading frames (ORFs) that are absent in the genome of BCG vaccine strains (Behr et al., 
1999). These ORFs are clustered in 16 regions of deletion (RDs). A total of 61 ORFs (clustered in 
4 
9 RDs) are missing in all M. bovis strains, including BCG, and 29 ORFs are missing in some BCG 
strains only. There are 39 ORFs (clustered in 3 RDs) that are missing in all BCG strains. Clearly, 
the M. tuberculosis ORFs that are absent in BCG represent candidates not only for virulence 
factors, but also for protective antigens. For instance, three genomic RDs were identified to be 
present in virulent M. bovis, M. tuberculosis and BCG - RD1, RD2 and RD3 (Mahairas et al., 
1996). Among these, the RD1 region seems to be most interesting for the specific diagnosis of 
TB because the genes predicted in this genomic DNA segment are deleted from all the vaccine 
strains of BCG, while they are conserved in all of the tested virulent laboratory and clinical 
isolates of M. bovis and M. tuberculosis (Mahairas et al., 1996). The RD1 region of M. 
tuberculosis encodes two low molecular weight secretory proteins, the 10-kDa culture filtrate 
protein - CFP-10, and the 6-kDa early-secreted target antigen - ESAT-6, two-major T-cell antigens 
of M. tuberculosis (Arend et al., 2000a; Arend et al., 2000b; Mustafa et al., 1998). Not only the 
deletion of the RD1 locus attenuates the virulence of M. bovis, but also, conversely, re-
introduction of the M. tuberculosis-RD1 in the genome of M. bovis BCG increases the latter’s 
virulence and immunogenicity (Behr, 2002; Demangel et al., 2005; Pym et al., 2002). 
 
1.4. THE INNATE IMMUNE RESPONSE TO M. tuberculosis 
 
1.4.1. M. tuberculosis AND HOST PHAGOCYTE INTERPLAY 
Infection of a host with M. tuberculosis follows the inhalation of droplets (aerosols) 
containing a small number of bacilli (Kaufmann, 2001b). Since the main route of entry of the 
causative agent is the respiratory route, the resident macrophages of the lung (alveolar 
macrophages) are the primary cell type involved in the initial uptake of mycobacteria (Orme and 
Cooper, 1999). After inhalation of tubercle bacilli, alveolar macrophages ingest the bacilli through 
phagocytosis and often destroy them. Phagocytosis of mycobacteria was shown to be an active 
process, mediated by an array of different receptors expressed on the surface of phagocytes 
(Brightbill et al., 1999; Cambi et al., 2005; DesJardin et al., 2002; Ernst, 1998; Greenberg, 
1999; Kang et al., 2005; Swanson and Hoppe, 2004).  
Both in natural and experimental infections mycobacteria are found and proliferate 
essentially inside macrophages and dendritic cells (DCs), even though neutrophils and 
eosinophils have also been shown to phagocytose mycobacteria (Castro et al., 1991; Kisich et 
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al., 2002). Macrophages and DCs are the main cells harbouring mycobacteria, functioning 
simultaneously as host and effector cells. 
Following phagocytosis, mycobacteria are contained inside phagosomes, membrane-bound 
intracellular vesicles in which microorganisms can be killed and digested. The phagosome-
containing ingested bacterium is then fused to lysosomes that contain numerous hydrolytic 
enzymes and are very acidic organelles. Phagosome-lysosome fusion is a highly regulated event 
and constitutes a significant antimicrobial mechanism of phagocytes (Flynn and Chan, 2001). 
Mechanisms involved in killing of M. tuberculosis within the phagolysosomes of activated 
macrophages include the production of reactive oxygen intermediates (ROI) and nitrogen oxides 
(Flynn and Chan, 2001). Hydrogen peroxide (H2O2), one of the ROI generated by macrophages 
via the oxidative burst, was the first identified effector molecule that mediated mycobactericidal 
effects of mononuclear phagocytes (Walker L, 1981). The ability of ROI to kill M. tuberculosis, 
although well demonstrated in mice, remains to be confirmed in humans. Several studies have 
demonstrated that M. tuberculosis infection induces the accumulation of macrophages in the 
lung, accompanied by H2O2 production (North and Medina, 1998). Moreover, different strains of 
M. tuberculosis induce the production of different amounts of ROI, which was suggested to be 
associated with the virulence of the strains (Firmani and Riley, 2002; Laochumroonvorapong et 
al., 1997). 
Upon activation, phagocytes also generate nitric oxide (NO) and related reactive nitrogen 
intermediates (RNI) via inducible nitric oxide synthase (iNOS) using L-arginine as substrate. The 
role of RNI in defence against mycobacteria has been demonstrated following the observation 
that in genetically altered NOS gene knock-out mice, M. tuberculosis replicates much faster than 
in wild type animals (MacMicking et al., 1997). High levels of NOS2 expression have been 
detected in macrophages from broncho alveolar lavage of patients with active pulmonary TB 
(Nicholson et al., 1996). 
Following M. tuberculosis infection, programmed cell death also constitutes an effector 
mechanism of the macrophage (Lee et al., 2009b). Apoptosis contributes to host defence by 
eliminating a protected intracellular environment favourable to bacterial replication, forcing the 
infecting pathogen to re-establish residence in a naive host cell, and by packaging M. tuberculosis 
bacilli and specific molecules in apoptotic bodies. The subsequent engulfment of these apoptotic 
bodies by newly recruited macrophages and DCs promotes the control of infection and the 
induction of the adaptive immune response (Lee et al., 2009b). Phagocytosis of apoptotic bodies 
6 
derived from M. tuberculosis-infected macrophages by DCs could lead to the presentation of 
mycobacterial lipid and peptide antigens and subsequent activation of specific T-cells (Schaible et 
al., 2003), a process defined as “crosspriming” (Guermonprez and Amigorena, 2005). 
Remarkably, apoptotic bodies containing mycobacterial antigens have the capacity to protect 
mice from challenge by virulent M. tuberculosis (Winau et al., 2006). The importance of 
apoptosis in the host's innate immune response was underlined by a report showing that 
apoptotic cell death reduced mycobacterial viability, whereas necrotic cell death had no effect on 
bacterial viability (Fratazzi et al., 1997; Keane et al., 2002; Molloy et al., 1994). In line with these 
findings is a report demonstrating that the susceptibility of different mouse strains to 
mycobacterial infections could be linked to the capacity of infected macrophages to either 
undergo necrotic or apoptotic cell death upon infection, with the former imparting a susceptible 
phenotype and the latter a resistant phenotype (Pan et al., 2005). 
In order to survive in its host, M. tuberculosis has evolved several mechanisms to 
overcome the host macrophage defence mechanisms (Flynn and Chan, 2001; North and Jung, 
2004). These immune evasion strategies allow M. tuberculosis to survive inside the host cells, 
thus contributing to the virulence of this pathogen. M. tuberculosis interferes with host trafficking 
pathways by modulating events based mainly on the arrest of phagosome maturation (Houben et 
al., 2006). The non-fusogenicity of mycobacterial phagosomes is believed to be a major factor in 
the capacity of pathogenic mycobacteria to survive within the potentially hostile environment of 
the macrophages (Nguyen and Pieters, 2005; Vergne et al., 2004). By blocking its delivery to 
lysosomes, M. tuberculosis is able to avoid the acidic proteases of the lysosomes, avoid exposure 
to the bactericidal mechanisms that operate within lysosomes, prevent degradation and hence 
processing and presentation of mycobacterial antigens to the adaptative immune system 
(Pancholi et al., 1993; Pieters, 2001). Another strategy apparently used by mycobacteria to 
modulate host immune responses in order to avoid the bactericidal activity of phagocytes (Chan 
J., 1994) is the production of superoxide dismutase and catalase that detoxify ROI (Andersen et 
al., 1991). In addition, mycobacterial components such as sulphatides, lipoarabinonannan (LAM) 
and phenolic-glycolipid I (PGLI) are potent oxygen radical scavengers (Chan et al., 1991; Chan et 
al., 1989).  
M. tuberculosis was also shown to inhibit host cell apoptosis (Balcewicz-Sablinska et al., 
1998; Fratazzi et al., 1999; Sly et al., 2003; Spira et al., 2003). Upon infection, M. tuberculosis 
was demonstrated to induce the up-regulation of anti-apoptotic genes that encode for Bcl-2-like 
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proteins (Spira et al., 2003). Other studies have shown that the expression of anti-apoptotic 
proteins is upregulated in cells infected with virulent strain of M. tuberculosis H37Rv, but not with 
the avirulent strain M. tuberculosis H37Ra (Spira et al., 2003), while pro-apoptotic proteins are 
inactivated following M. tuberculosis-H37Rv infection (Maiti et al., 2001). In order to inhibit tumor 
necrosis factor (TNF)-induced apoptosis, M. tuberculosis-infected macrophages have been 
reported to exhibit increased secretion of soluble TNFR2 (sTNFR2). The sTNFR2 binds to TNF in 
the extracellular milieu and thus inhibits its binding to the TNFR1 (Balcewicz-Sablinska et al., 
1998; Fratazzi et al., 1999). 
The interaction of DCs with the infectious agents plays a vital role in the initiation of the 
immune response against the pathogens (Lopez-Bravo and Ardavin, 2008). Although M. 
tuberculosis is able to grow equally well within DCs and macrophages, and activated DCs and 
macrophages were equivalent in their ability to inhibit replication of M. tuberculosis in an NOS2-
dependent manner (Bodnar et al., 2001), DCs interact with live M. tuberculosis bacilli in a 
manner different from that of macrophages. DCs are considered to be the professional antigen 
presenting cells (APC), due to their ability to endocytose antigens and express abundant 
quantities of MHC class II, co-stimulatory molecules, and cytokines (Giacomini et al., 2001), that 
all together drive T helper (Th) cell differentiation. Previous studies have revealed that human and 
murine DCs can ingest M. tuberculosis, and that DCs exposed to M. tuberculosis in vitro undergo 
a typical maturation program and upregulate their antigen-presenting activities (Bodnar et al., 
2001; Demangel et al., 1999; Demangel and Britton, 2000; Giacomini et al., 2001; Gonzalez-
Juarrero and Orme, 2001; Tascon et al., 2000). In addition, it was shown that DCs, but not 
macrophages, infected with M. tuberculosis are capable of driving Th1 polarization of naive CD4+ 
T cells (Hickman et al., 2002). Therefore, it is likely that DCs play an important role in initiating 
the acquired immune response to M. tuberculosis. An additional property of DCs that contributes 
to their effectiveness in initiating immune responses in vivo is their ability to migrate from 
peripheral tissues to secondary lymphoid tissues after acquiring antigens and in the presence of 
proinflammatory stimuli (Alvarez et al., 2008). Infection of DCs by M. tuberculosis results in the 
expression of CCR7 and subsequent migration of these cells to the lymph node (Bhatt et al., 
2004). Maturation and migration of DCs from the lung to the draining lymph nodes is a key step 
for the initiation of naive T cell activation (Bhatt et al., 2004; Chackerian et al., 2002; Demangel 
et al., 2002; Humphreys et al., 2006; Khader et al., 2006; Skold and Behar, 2008; Winslow et 
al., 2008; Wolf et al., 2008). 
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In summary, upon infection of the host, alveolar macrophages become activated and 
initiate several effector mechanisms that aim at eliminating M. tuberculosis. Soon after, DCs 
become exposed to M. tuberculosis in the lung, maturate and migrate to the draining lymph 
nodes where the initiation of the T cell response takes place. The understanding of the interaction 
of the pathogen with both macrophages and DCs is therefore important to provide clues on 
possible ways to modulate both the innate and the acquired immune responses. These steps of 
pathogen recognition, phagocytosis by macrophages and presentation by DCs are of particular 
importance for the understanding of the immune response to M. tuberculosis versus BCG.  
 
1.4.2. ROLE OF TLR SIGNALLING FOR M. tuberculosis RECOGNITION 
Early recognition of M. tuberculosis or mycobacterial products is a crucial step for the 
initiation of an effective host response. Recognition of infectious agents depends on a variety of 
pattern recognition receptors (PRRs) (Akira et al., 2006; Bhatt and Salgame, 2007; Geijtenbeek 
et al., 2003; Rothfuchs et al., 2007). Several PRRs have been involved in the recognition of M. 
tuberculosis by macrophages and DCs. This is the case of toll-like receptors (TLRs) 2, 4 and 9 
(Bafica et al., 2005; Pai et al., 2004; Quesniaux et al., 2004); dectin-1 (Lee et al., 2009a; 
Rothfuchs et al., 2007; Yadav and Schorey, 2006); the mannose receptor (Desjardins et al., 
1994; Kang et al., 2005); DC-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
(DC-SIGN) (Maeda et al., 2003; Tailleux et al., 2003) and nucleotide-binding oligomerization 
domain (NODs) (Ferwerda et al., 2005). Of these, the better characterised interaction is the one 
mediated by TLRs. Accumulating data indicate that M. tuberculosis expresses a large repertoire 
of TLR2 ligands. The 19-kDa lipoprotein (LpqH), a secreted antigen of M. tuberculosis, was the 
first M. tuberculosis ligand shown to interact specifically with TLR2 and to induce TNF and nitric 
oxide production from both murine and human macrophages (Brightbill et al., 1999). In addition, 
the 19-kDa lipoprotein is a major inducer of IL-12 production in human monocytes (Brightbill et 
al., 1999). Abel et al. demonstrated that phosphatidylinositol mannoside (PIM) structures can 
also elicit cellular activation via TLR4 (Abel et al., 2002), with the induction of nuclear factor-kB 
(NF-kB) activation in a dose dependent manner. Interestingly, mannose-capped 
lipoarabinomannan (ManLam) derived from virulent M. tuberculosis fails to activate either TLR2- 
or TLR4-transfected cells (Means et al., 1999). In contrast, arabinosylated lipoarabinomannan 
(AraLAM) purified from fast-growing mycobacteria is capable of TLR2-mediated cellular activation 
(Means et al., 1999). 
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Binding of TLR ligands to TLRs activate downstream signalling cascades through the 
adaptor protein myeloid differentiation protein 88 (MyD88), which links to IL-1R-associated kinase 
(IRAK), a serine kinase that activates transcription factors like NF-kB to signal the production of 
inflammatory cytokines and chemokines (O'Neill and Bowie, 2007), needed to promote the 
attraction of innate immune cells and the initiation and polarization of adaptive immune 
responses (Akira et al., 2006). The mitogen-activated protein kinases (MAPK) family, composed 
of the ERK1/2, p38 and SAPK/JNK pathways, has have been implicated in the mediation of 
TLRs signalling and activation of cytokine gene transcription (Liu et al., 2007). Several reports 
have shown that mycobacteria in general activate the MAPK pathway (Chan et al., 2001; Cobb, 
1999; Jones et al., 2001a; Jones et al., 2001b). For instance, Jones and colleagues 
demonstrated that AraLAM, isolated from avirulent mycobacteria, and PIM, isolated from M. 
tuberculosis, stimulated ERK1/2 phosphorylation and activated the transcription factors NF-kB 
and AP-1 in a murine macrophage cell line, in a TLR2-dependent manner (Jones et al., 2001a; 
Jones et al., 2001b). In addition, Chan and colleagues shown that, although ERK1/2 and p38 
were phosphorylated, activation of ERK1/2 was sufficient for the induction of the NOS2 gene 
following the stimulation of a macrophage cell line with both ManLAM and interferon (IFN)- 
(Chan et al., 2001). Mycobacteria are able to modulate MAPK signalling to promote their survival 
in the host cell. Several studies show that virulent strains of mycobacteria caused greater 
inhibition of MAPK, particularly the ERK1/2 pathway, as compared to avirulent strain (Florido et 
al., 1999; Hasan et al., 2003; Roach and Schorey, 2002). 
The relevance of TLR signalling for the development of the immune response to M. 
tuberculosis has been addressed in several studies in vitro and in vivo. MyD88 was found to be 
essential for M. tuberculosis-induced macrophage activation (Fremond et al., 2004; Scanga et 
al., 2004; Shi et al., 2003). In addition, M. tuberculosis-infected MyD88-deficient mice have 
increased numbers of bacteria in the lung in comparison to wild type controls (100 to 1000-fold) 
(Fremond et al., 2004; Scanga et al., 2004; Sugawara et al., 2003b). As for TLR2, its role in the 
infection by M. tuberculosis remains controversial. In a model of low-dose aerosol infection, TLR2 
deficiency did not affect host defence against M. tuberculosis infection (Reiling et al., 2002; 
Sugawara et al., 2003a). However, with high-dose aerosol infection, a role for TLR2 in host 
resistance was revealed (Reiling et al., 2002; Sugawara et al., 2003a). TLR2-deficient mice were 
not compromised in their ability to induce Th1 immunity, but on the contrary, exhibited 
exaggerated immunopathology (Reiling et al., 2002). In vitro studies have shown that 
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engagement of TLR2 with M. tuberculosis ligands induces inhibition of macrophage MHC class II 
antigen presentation (Noss et al., 2001) and also blocks macrophage responsiveness to IFN-γ 
(Banaiee et al., 2006; Fortune et al., 2004). Together with the in vivo studies, these in vitro 
findings suggest that TLR2 signalling negatively modulates macrophage functions. Recent data 
indicate that TLR9 cooperates with TLR2 to recognize M. tuberculosis in macrophages as well as 
splenic DCs (Bafica et al., 2005). When murine TLR9_/_ splenic DCs were stimulated with live M. 
tuberculosis, there was a partial reduction in IL-12p40 (Bafica et al., 2005). However, in TLR2/9 
double deficient cells, there was further inhibition of cytokine production to background levels, 
suggesting that the majority of TLRs-mediated mycobacterial signalling is through these two 
receptors (Bafica et al., 2005). Moreover, TLR2/9 double deficient mice displayed markedly 
enhanced susceptibility to infection (Bafica et al., 2005). Interestingly, TLR2/4 double deficient 
mice have been found to display unimpaired resistance to M. tuberculosis (Shi et al., 2005) as 
well as to BCG infection (Nicolle et al., 2004). In what regards BCG infection, in some studies 
TLR2, TLR4 and TLR6 were shown to be redundant for the control of infection (Fremond et al., 
2003; Heldwein et al., 2003; Nicolle et al., 2004). However, in another study TLR2 appears to be 
necessary for the expansion of effector T cells and for the induction of IFN- secretion by these 
cells, while, TLR4 was shown to be necessary for the development of a normal Th1 response 
against BCG, however only when larger bacterial numbers are encountered by the host (Heldwein 
et al., 2003). 
 
1.5. ROLE OF CD4+ T CELLS AND CYTOKINES IN THE INFECTION BY M. 
tuberculosis 
The protective response against TB requires cell-mediated immunity (Boom, 1996; 
Cooper, 2009a; Flynn and Chan, 2001; Kaufmann, 2001a). Among T lymphocytes, the CD4+ T-
cell subset is of primary importance in the protection against M. tuberculosis (Saunders et al., 
2002). Studies in mouse models deficient in CD4+ T cells clearly demonstrated that these cells 
are required for the control of infection (Saunders et al., 2002). In addition, other studies 
demonstrated that adoptive transfer of CD4+ T cells enhanced protection against TB (Orme and 
Collins, 1984). Moreover, the high numbers of individuals co-infected with HIV and M. 
tuberculosis strongly suggest that the loss of CD4+ T cells greatly increases the susceptibility of 
human hosts to both acute TB and to reactivation of TB (Jones et al., 1993; Lawn et al., 2002).  
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Upon aerosol infection with M. tuberculosis, the acquired cellular response is show to be 
induced in the lung, and dissemination of the mycobacteria from the lung to the draining lymph 
node has been suggested to be required for the activation of antigen-specific T cells and the 
induction of effector function (Bhatt et al., 2004; Chackerian et al., 2002; Demangel et al., 2002; 
Humphreys et al., 2006; Khader et al., 2006; Skold and Behar, 2008; Winslow et al., 2008; Wolf 
et al., 2008). This migration of DCs to the lymph nodes during mycobacterial infection appears to 
be promoted by IL-12p40 homodimers (Khader et al., 2006) and limited by IL-10 (Demangel et 
al., 2002). Following infection by mycobacteria, two subsets of CD4+ Th cells have been shown to 
differentiate in the lymph node and to subsequently migrate to the infected tissue to exert their 
effector activities. These subsets are Th1 (Cooper et al., 1995; Flynn et al., 1995) and Th17 
(Khader et al., 2005) cells. The differentiation of Th1 cells is determined mainly by the presence 
of IL-12, and results in the production of high levels of IFN-γ (O'Garra and Robinson, 2004). In 
the presence of transforming growth factor (TGF)- and IL-6, naive T cells differentiate into a 
Th17 phenotype that produces high levels of IL-17 and requires IL-23 for survival (Veldhoen and 
Stockinger, 2006). 
The expression of IL-12, IL-6 and IL-23 is mainly associated with cells of the innate 
immune response. IL-12 is a heterodimeric cytokine consisting of the two subunits IL-12p40 
(p40) and IL-12p35 which are covalently linked (Trinchieri, 2003). IL-12 expression is induced 
following phagocytosis of M. tuberculosis bacilli in macrophages and DC (Henderson et al., 1997; 
Ladel et al., 1997). Two studies comparing murine macrophages and DC demonstrated that DC 
release significantly higher amounts of IL-12 than did macrophages in response to live M. 
tuberculosis (Giacomini et al., 2001; Hickman et al., 2002). In vitro, M. tuberculosis-infected DC 
also primed naive T cells toward Th1 development, while macrophages did not (Verreck et al., 
2004). IL-23 is another cytokine of the IL-12 family (Hunter, 2005) and, as IL-12, is a 
heterodimeric cytokine composed by the p40 subunit covalently linked to a p19 subunit . IL-23 
secretion in response to TLRs activation appears to be more pronounced in DC than in 
macrophages (Gerosa et al., 2008; Jang et al., 2008; Lyakh et al., 2008). Interestingly, secretion 
of IL-12 and IL-23 by M. tuberculosis stimulation of DC can, in addition to TLRs, be also 
dependent on signals mediated by Dectin-1 (Gerosa et al., 2008; Rothfuchs et al., 2007; Zenaro 
et al., 2009). 
Several studies highlight the role of IL-12, IL-23, IL-6 and of IFN- and IL-17 during the 
course of infection. A role for IL-12 and cytokines of the Th1 axis, predominantly IFN-, is 
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established in protection against mycobacterial infections in both mouse models (Cooper, 2009a; 
Flynn et al., 1993) and human disease (Casanova and Abel, 2002; Flynn and Chan, 2001) 
(Cooper, 2009b). In particular, IFN- that in addition to Th1 cells can also be produced by natural 
killer (NK) cells (Scharton and Scott, 1993) and CD8+ T cells (Barnes et al., 1993; Lalvani et al., 
1998; Orme et al., 1992) is also the hallmark molecule for protection against TB (Chackerian et 
al., 2002; Cooper et al., 1993; Ellner et al., 2000; Flynn et al., 1993; Ottenhoff et al., 1998). The 
role of IL-23 and Th17 responses in the infection by M. tuberculosis is yet not fully understood. 
Studies performed in mice lacking p40, p35, p19 or combinations of these genes, showed that 
IL-23 is less critical than IL-12 for protection against M. tuberculosis, and only provides a 
moderate level of protection to the host in the absence of biologically active IL-12 (Khader et al., 
2005). IL-17, secreted not only by CD4+ Th17 cells (Khader et al., 2007), but also by  T cells 
(Lockhart et al., 2006), has been shown to have a limited role in host defense against M. 
tuberculosis during primary infection (Aujla et al., 2007). However, vaccination has been shown 
to trigger an IL-17-dependent accelerated IFN- response by CD4 T cells in the lung during 
subsequent M. tuberculosis infection (Khader et al., 2007). Importantly, IL-17 promotes 
neutrophil recruitment to the site of infection (Fossiez et al., 1996; Jones and Chan, 2002; Ye et 
al., 2001), but this ability of IL-17 to induce chemokine production and cell recruitment to the 
infected tissue can in certain situations be associated with the development of immune pathology 
(Cooper, 2009a) (Cruz et al, umpublished data). 
Another important cytokine with a key role in the immune response to M. tuberculosis is 
TNF. M. tuberculosis induces TNF secretion by macrophages, DC and T cells (Barnes et al., 
1993; Henderson et al., 1997; Ladel et al., 1997; Serbina and Flynn, 1999). The requirement 
for TNF for the control of M. tuberculosis infection is complex, but it clearly is an important 
component for macrophage activation, as TNF, in synergy with IFN-, induces NOS2 expression 
(Chan et al., 1992; Liew et al., 1990). The importance of this cytokine in granuloma formation in 
TB and other mycobacterial diseases has been significantly documented (Flynn and Chan, 2001; 
Miller and Ernst, 2008).  
The proinflammatory response which is initiated by M. tuberculosis is antagonized by anti-
inflammatory cytokines that contribute to the control of the magnitude of the inflammatory 
responses. TGF- was found to be present in granulomatous lesions of TB patients and is 
produced by human monocytes after stimulation with M. tuberculosis (Toossi et al., 1995) or M. 
tuberculosis lipoarabinomannan (Lam) (Dahl et al., 1996). TGF- has important anti-
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inflammatory effects, including deactivation of macrophage production of ROI and RNI (Ding et 
al., 1990), inhibition of T cell proliferation (Toossi and Ellner, 1998), interference with NK and 
CTL function and downregulation of IFN- (Ruscetti et al., 1993), TNF and IL-1 release (Ruscetti 
et al., 1993). TGF-β is also an important mediator of immune-suppression by regulatory T cells 
(Gorelik and Flavell, 2002). However, together in the presence of IL-6, TGF- induces Th17 
differentiation (Veldhoen et al., 2006).  
The anti-inflammatory cytokine IL-10 is also expressed during M. tuberculosis infection 
(Barnes et al., 1993; Boussiotis et al., 2000; Gerosa et al., 1999; Shaw et al., 2000). IL-10 is 
needed to limit tissue damage by controlling the immune response (Moore et al., 2001). 
However, an excess of IL-10 most likely prevents pathogen clearance. Indeed, transgenic mice 
constitutively expressing IL-10 were less capable of clearing a BCG infection, although T cell 
responses including IFN- production were unimpaired (Murray et al., 1997), thus suggesting 
that IL-10 may counter the macrophage activating properties of IFN- . Interestingly, IL-10-/- mice 
were not more resistant to acute M. tuberculosis, compared to wild type mice (North, 1998). 
However, lack of IL-10 was recently link to a decreased control over the inflammatory response 
that eventually resulted in progression of disease, bacterial multiplication and morbidity (Higgins 
et al., 2009). 
An appropriate immune response to M. tuberculosis is the result of a balance between 
inflammation and regulation. In what extent does the vaccination with BCG change the 
parameters of this response is still not fully known. This knowledge is however important in order 
to improve the efficacy of BCG vaccination or to develop new vaccination strategies. 
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II. AIMS 
 
BCG is the only approved vaccine used for TB prevention. Although BCG is used 
worldwide, the cellular and molecular mechanisms by which this vaccine acts are still poorly 
understood. Although BCG is protective against tuberculous meningitis, it shows great variability 
in the prevention of pulmonary disease. 
Several experimental vaccines are being developed against TB. Some are able to induce 
the same level of protection as BCG, although none were demonstrated to induce better 
protection than BCG. Therefore it is fundamental to understand how BCG modulates the innate 
and cellular immunity and where it fails, in order to improve vaccination strategies to TB. 
 
The main goal of this work was to perform a comparative study of BCG versus M. 
tuberculosis infection on DCs and macrophages to better understand how these pathogens 
interact with cells of the innate immune system, what molecular pathways are triggered, and how 
that interaction translates into an effective, or not, Th cell responses  
 
Specifically, the following aims were addressed: 
 
1. Investigation of the magnitude of macrophage and DCs responses to M. tuberculosis 
or BCG, in terms of cytokine production by these phagocytes; 
2. Elucidation of the molecular events that might explain differences in the cytokine 
response of macrophages and DCs to M. tuberculosis or BCG; 
3. Understanding the type of Th cell responses developed in the presence of M. 
tuberculosis- or BCG- infected DCs; 
4. Clarification of the effector activity of macrophages in what regards the control of M. 
tuberculosis or BCG growth. 
 
Dissecting the cellular and molecular events that occur upon mycobacterial challenge will 
help to reveal possible weak points of both the host and the bacteria that can be targeted and will 
subsequently provide clues for the design of new and better vaccines.  
16 
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III.  MATERIAL & METHODS 
 
3.1. Animals 
Eight-week-old female C57BL/6 and Balb/c mice were obtainned from Charles River 
Laboratory (Barcelona, Spain). Mice transgenic for the DO11.10 / TCR were backcrossed on 
a RAG-deficient (RAG 2/2) BALB/c background and were kindly provided by Dr. Anne O’Garra 
(NMIR, London, England). 
 
3.2. Bacteria 
The H37Rv strain of M. tuberculosis and M. bovis BCG Pasteur were grown in Proskauer 
Beck medium containing 0.05% Tween 80 to mid-log phase and frozen in 1-ml aliquots at -80ºC. 
Bacterial viability was determined by counting the number of CFU (colony forming units) on 
Middlebrook 7H11 agar plates. M. bovis BCG Pasteur were obtained from Trudeu Institute 
Mycobacterium Collection (TMC 1011). 
 
3.3. Culture of Bone Marrow Derived Macrophages 
Primary mouse bone marrow derived macrophages were generated from WT C57BL/6 
animals as described elsewhere(Saraiva et al., 2009). Petri dishses were initially seeded with 
1x105 cells in complete medium with 20% of L-929 conditioned medium (LCCM) and incubated 
at 37ºC in 5% CO2 humidified air chamber. On day 4, the medium was renewed and cultures 
were used at day 7. Macrophages were stimulated with M. tuberculosis or BCG at a multiplicity of 
infection (MOI) 2:1 (bacteria/macrophage) for different periods of time. Some cultures received 
100 U/ml of mouse IFN- (R&D Systems). 
 
3.4. Culture of Bone Marrow Derived Dendritic Cells  
Primary mouse bone marrow derived dendritic cells (DCs) were differentiated from WT 
C57BL/6 mice as described previously (Saraiva et al., 2009). Cells were culture in 6-well plates, 
containing 5x106 cells in complete medium with 20% of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and incubated at 37ºC in 5% CO2 humidified air chamber. On day 2, 
4 and 6, the medium was renewed and cultures were used at day 7. DCs were exposed to live M. 
tuberculosis  or BCG at a MOI of 2 for different periods of time.  
 
18 
3.5. Quantitative Real Time-PCR (RT-PCR) Analysis  
Total RNA from cultured macrophages was extracted with TRIzol® Reagent (Invitrogen, 
San Diego, CA) according to the manufacturer’s instructions. Reverse transcription was done with 
whole RNA in a final volume of 20 μl using SuperScript II (Invitrogen) and Oligo(dT) (Roche) 
according to the manufacturer’s instructions. The cDNA was then subjected to real-time PCR for 
quantification of IL-12p40, IL-12p35, IL23p19, TNF, IL-6, IL-10 and Ubiquitin (used as house-
keeping gene) in 10 µl with SYBR Green Supermix (Bio-Rad) in an CFX 96 Real-Time (Bio-Rad) 
system. The specific conditions of each PCR are listed in the table 1. All reaction were performed 
using the following cycling parameters: 1 cycle of 95ºC for 15 min, followed by 30 cycles of 95ºC 
for 15 min, 58ºC for 20 min and 72ºC for 15 min, and 2 amplification cycles of 65ºC for 1.3 min 
and 95ºC for 15min; and 1 cooling cycle of 35ºC for 1.3 min. Relative mRNA expression was 
calculated accordingly with the following equation: 1.8 ^ (ubiquitin mRNA expression – specific 
cytokine gene mRNA expression) x 100000. 
 
Table 1 - Sequence of the primers specific for genes and conditions used in RT-PCR 
reaction. 
 
 
 
 
 
 
 
 
 
 
3.6. ELISA Assay 
Supernatants from M. tuberculosis- or BCG-infected DCs were collected at 24h post-
infection and screened for IL-12p70, IL-12p40, IL-23p19, TNF, IL-6 or IL-10 Ready Set-Go ELISA 
kit (eBioscience) by sandwich ELISA. 
 
 
Gene Primer                                Probe Sequence 
Ubiquitin 
Sense 
Anti-sense 
5’- TGG CTA TTA ATT ATT CGG TCT GCA -3’ 
5’- GCA AGT GGC TAG AGT GCA GAG TAA -3’ 
IL-12p40 
Sense 
Anti-sense 
5’- CAA ATT ACT CCG GAC GGT TCA -3’ 
5’- AGA GAC GCC ATT CCA CAT GTC -3’ 
IL-12p35 
Sense 
Anti-sense 
5’- TGC TGG TGG CCA TCG AT -3’ 
5’- GCA GAG TCT CGC CAT TAT GAT TC-3’ 
IL-12p19 
Sense 
Anti-sense 
5’- CGT ATC CAG TGT GAA GAT GGT TGT -3’ 
5’- GCT CCC CTT TGA AGA TGT CAG A-3’ 
TNF 
Sense 
Anti-sense 
5’- GCC ACC ACG CTC TTC TGT CT -3’ 
5’- TGA GGG TCT GGG CCA TAG AAC -3’ 
IL-6 
Sense 
Anti-sense 
5’- ACA CAT GTT CTC TGG GAA ATC GT -3’ 
5’- AAG TGC ATC ATC GTT GTT CAT ACA -3’ 
IL-10 
Sense 
Anti-sense 
5’- TTT GAA TTC CCT GGG TGA GAA -3’ 
5’- GCT CCA CTG CCT TGC TCT TAT T -3’ 
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3.7. Protein Analysis 
Macrophages and DCs were cultured in medium containing 1% FBS overnight before 
stimulation with M.tuberculosis or BCG and washed in PBS before lysis (1% NP-40, 0.1% SDS, 
0.5% deoxycholate acid, 50 mM Tris HCl, pH 8.0, 50 mM NaCl, 2 mM EDTA, 2 mM sodium-
pyrophosphate, 50 mM sodium fluoride, 100 mM vanadate [all from Sigma-Aldrich], and 
complete EDTA-free protease inhibitor cocktail (Roche). Immunoblotting of proteins was 
performed as previously described (Saraiva et al., 2005) and visualized with ECL (GE Healthcare) 
or SuperSignal West Femto Substrate (Thermo Fisher Scientific). Using specific antibodies that 
exclusively recognize the bi-phosphorylated forms (activated) of ERK1/2 or the total form of the 
same enzyme, the ratio between the Western Blot signals obtained for the phosphorylated versus 
the total form, allow the quantification of the amount of ERK1/ERK2 activated within the cells 
upon M. tuberculosis or BCG stimulation. Antibodies used: rabbit (polyclonal) anti-ERK1/2 
[pTpY185/187) phosphospecific (Biosource), rabbit (polyclonal anti-ERK1/2 pan (Biosource). 
 
3.8. In vitro CD4 T Cell Activation 
Naive CD4+ T cells were generated from OVA-TCR transgenic DO.11.10 mice as described 
(Cruz et al., 2006) and cultured (1x106 cells/ml) with M. tuberculosis- or BCG- infected DCs 
(1x106 cells/ml) for 72h at 37°C in 5% CO2, and  in 10 ng/ml IL-2 and 5 M OVA323–339 peptide. 
Stimulated T cells were washed and counted, and the frequency of IFN-- and IL-17-producing 
CD4+ T cells determined by ELISPOT. 
 
3.9. In vivo Infection 
C57BL/6 animals were infected by the intravenous route with M. tuberculosis strain 
H37Rv or with BCG (1x106 CFU) and at different time points the animals were sacrificed and the 
spleens removed. The ability of the splenocytes to produce IFN- or IL-17 in response to Antigen 
85 was assessed by ELISPOT. 
 
3.10. ELISPOT Assay 
ELISPOT was performed as described previously (Cruz et al., 2006). Briefly, a total of 
1x105 cells was added to Ab-coated wells, 2-fold dilutions were made, and irradiated splenocytes 
from Balb/6 or C57/BL6 mice were added at 1x106 cells per well. A peptide representing an I-Ab-
restricted epitope of antigen85A (Cole et al., 1998) were used to stimulate cells from infected 
20 
mice, whereas Ova323–339 stimulated DO.11.10 T cells (Camus et al., 2002); all wells contained 10 
ng/ml IL-2. After 24 h, plates were washed and the number of IFN-- or IL-17-producing CD4+T 
cells determined as described (Cruz et al., 2006). Cells from mice infected with M. tuberculosis 
or BCG, but cultured in the absence of antigen, did not produce spots. 
 
3.11. Bacterial Load Determination 
To determined the number of viable bacteria, macrophage monolayers were lysed with 
0.1% (final concentration) saponin and the bacterial suspensions were serially diluted and plated 
onto Middlebrook 7H11 agar medium. Bacterial colony formation was counted after 3 weaks of 
incubation at 37°C. 
 
3.12. Nitrites Quantification 
Nitrite production by macrophage monolayers was determined by the colorimetric Griess 
assay as described elsewhere (Turner et al., 2001). Briefly, supernatants from macrophage 
cultures were placed into 96-well enzyme-linked immunosorbent assay plate in duplicates, and 
equal volume of Griess reagent (1% sulfanilamine, 0.1% nathylethylenediamine, 2,5% H3PO4) was 
added. The absorbance was measured at 550nm on a spectrophotometer, and the 
concentrationof nitrite was calculated by comparing optimal density values to a standard curve of 
NaNO2. 
 
3.13. Immunofluorescence 
Macrophages were cultivated as described above except that lamellae were placed on the 
bottom of the wells of the 24-wells incubation plaques. At specific time points after infection, the 
lamellae were collect and fixed in 2% PFA. Next, the lamellae were incubated with the primary 
antibody affinity-purified rabbit anti-human/mouse caspase 3 active (R&B Systems) and was 
detected with goat anti-rabbit IgG (H+L) Alexa Fluor 568 (Molecular Probes A11011). DAPI was 
used to counter stained and to detect nuclei. Pictures were observed with Olympus BX61 
microscope and images were recorded with Olympus DP70 camera.  
 
3.14. Stastistical Analysis 
The results are given as means ± SE of the mean. Statistical significance was performed 
by using Studant’s t test. Values of p < 0.05 were considered significant.  
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IV. RESULTS 
 
4.1. DC responses to M. tuberculosis and to BCG are stronger than macrophage 
responses, and M. tuberculosis is a stronger stimulus than BCG to DCs 
To understand the early steps of the immune response to M. tuberculosis and BCG and 
since DCs and macrophages are the central sensory components of the immune system, being 
within the first cells to recognize the presence of pathogens and to respond to it, we decided to 
compare the response of both cells types to either M. tuberculosis or BCG in a systematic and 
extensive fashion.  
The first point to be addressed in our comparison was the response of macrophages and 
DCs to M. tuberculosis or BCG in terms of cytokine production. To do this, we prepared primary 
cultures of macrophages and DCs derived from mouse bone marrow and stimulated with live M. 
tuberculosis or BCG at a MOI of 2. At different time points post-infection, we extracted RNA from 
the stimulated cells, prepared cDNA and measured the expression of several cytokines by RT-
PCR. We were particularly interested in studying whether the expression of cytokines with a role 
in T cell differentiation induced by M. tuberculosis or BCG was different. Since IL-12p70 and IL-
23 are important for Th1 and Th17 responses, respectively, we started by measuring the 
transcription of the monomers that compose IL-12 and IL-23 (p40-p35 and p40-p19, 
respectively). We also measured the expression of other immune mediator cytokines such as 
TNF, which contributes to the initial control of the infection, for example by activating the infected 
macrophages in an autocrine way (Chan et al., 1992; Liew et al., 1990); IL-6 described to be 
required for the development of Th17 cells (Veldhoen and Stockinger, 2006); and IL-10, an anti-
inflammatory cytokine known to inhibit macrophage and DCs functions (Demangel et al., 2002; 
Madura Larsen et al., 2007). 
As shown in Fig.1, we observed that both macrophages and DCs express various cytokines 
in response to M. tuberculosis or BCG. Both cell types showed similar patterns of expression for 
p35, TNF, IL-6 and IL-10 in response to either mycobacterium. However, major differences were 
identified in terms of the IL-12 subunits p40 and p19. Indeed, whereas macrophages stimulated 
with M. tuberculosis or with BCG did not express detectable amounts of IL-12p19 monomer, DCs 
did express this molecule, but the levels obtained in response to M. tuberculosis stimulation were 
higher than those obtained with BCG stimulation. In what regards the expression of IL-12p40, the 
pattern was similar to the one observed for p19. Again, maximum p40 expression was induced 
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by M. tuberculosis in DCs. BCG induced only modest amounts of p40 in DCs and the expression 
of this molecule by macrophages was low, but detectable. Interestingly, M. tuberculosis-
stimulated DCs, always expressed higher levels of the tested cytokines, suggesting that M. 
tuberculosis is stronger than BCG as a stimulus to DCs. As for macrophages, the two agents 
yielded similar responses, thus suggesting that different regulatory pathways are in place in 
macrophages versus DCs. Overall, our data show a differential cytokine expression by 
macrophages and DCs when stimulated with M. tuberculosis or BCG. 
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Figure 1 - M. tuberculosis and BCG are stronger stimuli to DCs than to macrophages, and M. tuberculosis is a stronger stimulus than BCG to DCs.
Macrophages and DCs were generated from BL/6 mice and exposed to M. tuberculosis or BCG at an MOI of 2. At different time points post infection, total RNA was extracted. The
expression of IL-12p40, IL-12p35, IL-23p19, TNF, IL-6 and IL-10 was assessed by RT-PCR and normalised to the expression of ubiquitin. Points of the graphs represent pools of
cells in each time point (n=3). Results are representative of three independent experiments with similar results. Mtb (M. tuberculosis); ND (not detected).
Macrophages MacrophagesDCs DCs
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4.2. M. tuberculosis-stimulated DCs are stronger producers of IL-12 and IL-23 than 
BCG-stimulated DCs. 
From our mRNA analysis, we concluded that the transcription of p40 and p19 by DCs was 
only induced in relevant levels by M. tuberculosis stimulation. Taking into consideration the role 
of IL-12 (p40-p35) and IL-23 (p40-p19) molecules in Th cell differentiation, we decided to assess 
the secretion of IL-12p70 and IL-23 by M. tuberculosis or BCG stimulated DCs. For that, we 
collected DCs culture supernatants 24 hours post-stimulation and measured by immunoassay 
the amounts of cytokines secreted. Consistently with the observed gene expression pattern, the 
analysis of supernatants from stimulated DCs showed that both IL-12p70 and IL-12p40 release 
was higher in DCs stimulated with M. tuberculosis comparing to stimulation with BCG (Fig. 2). IL-
23 production was only detectable in M. tuberculosis-stimulated DCs. We also measured the 
secretion of TNF, IL-6 and IL-10. We found that IL-6 and IL-10 production was similar in both M. 
tuberculosis- and BCG-stimulated DCs, but TNF production was higher in DCs stimulated with 
BCG (Fig.2). Thus our data suggest that, in terms of protein expression, M. tuberculosis-
stimulated DCs are potent producers of IL-12 and IL-23 whereas BCG-stimulated DCs are not. 
Importantly, our data also show that, despite the difference observed for IL-12 and IL-23, BCG is 
able to induce the production of certain cytokines by DC, thus suggesting that activation signals 
can be generated by BCG. We are currently performing the ELISA assays for macrophages 
supernatants to further validate the results obtained by PCR. 
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Figure 2 - M. tuberculosis infected DCs produce higher amounts of IL-12 and IL-23 than 
BCG-infected DCs. DCs were differentiated from WT mice and exposed to M. tuberculosis or BCG at an 
MOI of 2. DCs culture supernatants were harvested 24 hours post stimulation and analyzed by ELISA for 
IL-12p70, IL-12p40, IL-23, TNF, IL-6 and IL-10 concentration. Each time point represents the mean of 
three wells. Results are representative of three independent experiments with similar results and show 
mean ± SD; *, **, p<0.05 and 0.01, respectively. Mtb (M. tuberculosis). ND (not detected) 
 
4.3. M. tuberculosis induces earlier and stronger activation of ERK 
phosphorylation in macrophages as compared to DCs 
From the results shown in the previous sections, macrophages and DCs respond 
differently to M. tuberculosis or BCG stimulation in terms of cytokine expression, particularly in 
what regards the expression of IL-12 and IL-23 (Fig.1 and Fig.2). We hypothesised that these 
differences might be a consequence of a differential activation of intracellular signalling cascades. 
Previous studies have suggested the activation of various signalling cascades following 
mycobacterial infection, such as the MAPK pathway (Cobb, 1999) that includes three main 
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cellular kinases: ERK, p38 and JNK. We have started by addressing the activation of the MAPK 
cascade induced by M. tuberculosis or BCG by monitoring the ERK pathway. Phosphorylation of 
the two isoforms, ERK1 and ERK2, induces their translocation to the nucleus, followed by 
activation of several targets and culminating with the expression of cytokine genes. Thus, to 
further investigate if ERK activation is differently induced by M. tuberculosis and BCG in 
macrophages and DCs, we measured the phosphorylation of this MAPK by Western Blot, using 
specific antibodies that exclusively recognize the bi-phosphorylated forms (activated) of 
ERK1/ERK2 or the total form of the same enzyme. To control the amount of total protein used, 
we detected the amount of actin present in each condition, in parallel to phosphor-ERK1/2 or 
total-ERK1/2. The ratio between the Western Blot signals obtained for the phosphorylated versus 
the total form, allowed the quantification of the amount of ERK1/ERK2 activated within the cells 
upon M. tuberculosis or BCG stimulation. As shown in Fig.3, M. tuberculosis stimulation of 
macrophages induced an earlier and stronger ERK phosphorylation than that induced in DCs. 
Although the kinetics of ERK phosphorylation was similar for M. tuberculosis- or BCG-stimulated 
macrophages, this activation was weaker when BCG was used as stimulus. The lowest induction 
of ERK phosphorylation was observed in DCs stimulated with BCG. Therefore our results suggest 
that M. tuberculosis and BCG trigger the ERK pathway with distinct intensities in macrophages 
and DCs. Despite the higher levels of ERK phosphorylation observed for macrophages, these 
cells do not respond to M. tuberculosis in a stronger way than DCs, suggesting that tight 
regulatory mechanisms must be in place. 
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Figure 3 – M. tuberculosis-stimulated macrophages earlier and stronger activate ERK 
phosphorylation as compared to DCs. Mouse DCs and macrophages were differentiated in culture 
and stimulated with M. tuberculosis or BCG at a MOI of 2. At the indicated time points, cellular extracts 
were prepared, proteins separated by SDS-PAGE and specific phosphorylation of ERK detected by Western 
Blot. Total ERK and actin proteins were detected as loading controls. Points of the graphs represent pools 
of triplicate cell cultures in each time point and are from one experiment. 
 
4.4. Differential Th responses are induced in vitro by M. tuberculosis- or BCG-
infected DCs  
The presence of IL-12 (p40-p35) and IL-6 or TGF- and IL-23 (p40-p19) in the cytokine 
milieu dictates the differentiation of Th1 or the differentiation and survival of Th17 responses, 
respectively (Veldhoen and Stockinger, 2006). Since M. tuberculosis or BCG stimulation of DCs 
induced a differential expression pattern of IL-12 and IL-23, but similar levels of IL-6 (Fig.1 and 
Fig.2), we decided to investigate if this difference resulted in differential Th responses developed 
in the presence of M. tuberculosis or BCG. A difficulty in studying early T cell differentiation is the 
low number of antigen-specific T cells present during immune initiation. Thus, we used a well 
stabilised model, the DO11.10 TCR-transgenic mice that express a TCR specific for OVA323–339 
peptide (OVA peptide), to evaluate the impact of M. tuberculosis or BCG infection on DCs-driven T 
cell differentiation. Bone marrow DCs were infected with M. tuberculosis or BCG (MOI of 2). 
Macrophages DCs 
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Twenty four hours later, the infected DCs were recovered and co-cultured with CD4+ T cells 
isolated from the spleens of DO11.10 TCR transgenic mice in the presence of OVA peptide and 
IL-2, following a previously reported method. Three days later, the CD4+ T cells were recovered 
and their cytokine profile, in terms of IFN- or IL-17 expression, determined by ELISPOT, using 
OVA peptide as antigen.  
We observed that M. tuberculosis-infected DCs were able to induce the development of 
both Th1 and Th17 responses, whereas BCG-infected DCs induced preferentially Th17 responses 
(Fig. 4). As a control, non-infected DCs induced undetectable Th1 responses and very few IL-17-
producing CD4+ T cells (Fig.4). All together, our data strongly suggest that the differential 
activation of DCs responses by M. tuberculosis or BCG, observed in terms of signaling cascades 
activated and of differential expression of certain cytokines, does have an impact in terms of Th 
cell differentiation.  
 
Figure 4 - Differential Th responses are induced in vitro by M. tuberculosis- or BCG-infected 
DCs. Purified DO11.10 transgenic CD4+ T cells were cultured for 3 days with DCs from Balb/c mice. The 
DCs were either previously infected with M. tuberculosis or BCG (MOI of 2) or left uninfected. All cultures 
contained OVA peptide and IL-2. After 3 days the cells were washed and the ability of the differentiated 
CD4+ T cells to produce IFN-γ or IL-17 in response to OVA peptide was determined by ELISPOT. Points of 
the graph represent pools of cells for each condition. Results show mean ± SD for ELISPOT dilutions from 
one experiment. Mtb (M. tuberculosis). 
 
4.5. M. tuberculosis and BCG induce a differential kinetics of Th responses kinetics 
in vivo 
Having observed in vitro that M. tuberculosis-infected DCs were able to induce the 
development of both Th1 and Th17 responses, whereas BCG-infected DCs preferentially induced 
Th17 responses in vitro, we wanted to explore if this observation had an in vivo parallel. To 
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investigate this, we infected mice intravenously with M. tuberculosis or BCG and at certain time 
points post-infection, the animals were sacrificed and their spleens harvested. Splenocyte 
suspensions from infected animals were prepared and restimulated ex vivo for 18 hours with a 
class I-Ab-restricted epitope of the dominant mycobacterial antigen, antigen85A, present in both 
BCG and M. tuberculosis. The splenocytes ability to produce IL-17 or IFN- was determined by 
ELISPOT. As shown in Fig.5, we observed a higher number of IFN--producing CD4+ T cells in M. 
tuberculosis-infected animals than in BCG-infected ones, for the tested time points. In contrast, 
BCG infection induced a higher number of IL-17-producing CD4+ T cells as compared with the M. 
tuberculosis infection. Our in vivo data are therefore in line with the in vitro findings, thus 
suggesting that the differential Th responses observed for M. tuberculosis and BCG might be an 
interesting point to address and explore in the future in terms of vaccine development. 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Differential Th responses are induced by M. tuberculosis or BCG during an in vivo 
infection. BL/6 mice were infected intravenously with 1x106 CFU of M. tuberculosis or BCG and at the 
indicated time points splenocytes were isolated and assessed for their ability to produce IL-17 or IFN-γ in 
response to antigen85 by ELISPOT. Results show mean ± SD from one experiment, *, **, ***, p<0.05, 
0.01 and 0.001, respectively. Mtb (M. tuberculosis). 
 
4.6. The growth of M. tuberculosis in infected macrophages is faster than the 
growth of BCG 
In the previous sections, we showed that the ability of BCG- or M. tuberculosis- infected 
DCs to differentiate CD4+ T cells into Th1 or Th17 cell responses was different, which was related 
to the differential response of these cells to each of the bacteria. We next questioned if the 
effector activity of macrophages in what regards the control of M. tuberculosis or BCG growth 
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was also different. To test this, macrophages were infected with these two mycobacteria (MOI of 
2) and on specific time points post-infection, the number of viable bacteria was determined. We 
observed an increase of bacterial burden on M. tuberculosis-infected macrophages, 2 days after 
infection. At this time point, macrophages infected with BCG showed significantly less bacterial 
burden. However, 4 days post-infection, the bacterial load observed for both M. tuberculosis- and 
BCG-infected macrophages was similar (Fig.6). Our results thus suggest that the effector activity 
of macrophages, able to control BCG during the initial time points of macrophage infection, might 
be compromised in infections by M. tuberculosis. 
 
 
 
 
 
 
 
 
Figure 6 – The growth of M. tuberculosis in infected macrophages is faster than the growth 
of BCG. Macrophages from BL/6 mice were differentiated and exposed to M. tuberculosis or BCG at a 
MOI of 2. At the indicated time points, cells were lysed and the number of viable bacteria assessed by 
CFU counting. Each point is the mean of 6wells. Results show mean ± SD from two experiments; ***, 
p<0.001. MTB (M. tuberculosis). 
 
4.7. The induction of NO by M. tuberculosis or BCG in infected macrophages is 
similar 
Having observed a significant increase in the bacterial burden of M. tuberculosis-infected 
macrophages, 2 days after infection, in contrast to macrophages infected with BCG, we wanted 
to determine if the bactericidal activity of macrophages was more effective against BCG than 
against M. tuberculosis at that specific time point. Since the anti-mycobacterial function of 
macrophages has been associated, among other mechanisms, to the production of NO (Flynn 
and Chan, 2001), we analysed the generation of NO by M. tuberculosis- or BCG- infected 
macrophages. Macrophages were infected with M. tuberculosis or BCG. As the microbicidal 
activity of macrophages is highly potentiated by IFN-, we performed the infections in the 
presence or absence of this cytokine. At specific time points after infection, culture supernatants 
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were harvested and mixed with Griess reagent and NO release measured by spectrophotometry, 
using dilutions of NaNO2 to obtain the standard curve. Infection by M. tuberculosis or BCG alone 
did result in detectable but very low levels of NO production. As expected, IFN- significantly 
increased the production of NO induced by both infections (Fig.7). However, the amount of NO 
released by macrophages upon infection by M. tuberculosis or BCG was similar. These results 
suggest that NO production most likely was not the effector mechanisms behind the increased 
protection observed on BCG-infected macrophages, at 2 days post-infection (Fig.6). Indeed, other 
bactericidal mechanisms of macrophages might account for the differential protection observed, 
as will be discussed later. 
 
 
 
 
 
 
 
 
Figure 7- M. tuberculosis- or BCG-infected macrophages produce similar amounts of NO 
along the first 48 hours post-infection. Macrophages were differentiated from BL/6 mice and 
infected with M. tuberculosis or BCG (MOI of 2) in the presence or absence of IFN-. On day 0 and on 
days 1 and 2 post-infection, culture supernatants were recovered and the amount of nitrites quantified by 
the Griess assay (Turner et al., 2001). Each time point represents the mean of three wells. Results show 
mean ± SD from two experiments. MTb (M. tuberculosis). 
 
4.8. M. tuberculosis induces high rates of caspase-3-mediated apoptosis at early time 
points post-infection 
As the levels of NO production by macrophages following infection with M. tuberculosis or 
BCG were similar, we decided to investigate if other bactericidal mechanism were more effective 
during BCG than M. tuberculosis infection. During mycobacterial infections, macrophage 
apoptosis is associated with protection (Lee et al., 2009b). Since caspase-3 has been identified 
as being a key mediator of apoptosis, we decided to measure caspase-3 activation on 
macrophages infected with M. tuberculosis or BCG, by immunocytochemistry. As observed in 
Fig.8, the percentage of caspase-3 positive macrophages increased with both infections during 
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the time of infection. However, 2 days post-infection, M. tuberculosis induced higher percentage 
of caspase-3 activation in macrophages. At 4 days post-infection, this percentage was similar in 
both M. tuberculosis and BCG infections. In contrast to what happened with BCG infection, where 
a significantly increase of caspase-3 positive cells was observed over-time, during M. tuberculosis 
infection the number of caspase-3 positive cells was at its maximum on day 2 post-infection. 
Therefore, despite the existence of more cells undergoing apoptosis at early time points during 
the infection by M. tuberculosis, the bacterial burden was higher for this bacterium than for BCG. 
Our data strongly suggest that apoptosis induced by M. tuberculosis early on post-infection is not 
associated with a protective response. 
 
 
 
 
 
 
 
Figure 8 –M. tuberculosis induces high rates of caspase-3-mediated apoptosis at early time 
points post-infection. Macrophages were differentiated and placed under lamellae on the bottom 
of the wells of 24-wells incubation plaques. At specific time points after infection, the lamellae 
were collect and fixed in 2% PFA. Subsequently, the lamellae were incubated with the primary 
antibody against caspase-3 and detected with anti-rabbit IgG (H+L). DAPI was used to counter 
stained and to detect nuclei by fluorescence microscopy. Results show mean ± SD from two 
experiments, **, p<0.01. MTb (M. tuberculosis). 
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V. DISCUSSION 
 
With one-third of the world’s population infected with M.tuberculosis, TB remains an 
important disease not only in terms of public health implications but also because it is a disease 
that persists in the host.  
The only vaccine currently available to prevent TB is BCG. It prevents disseminated TB in 
newborns, however fails to protect against the most common form of the disease, pulmonary TB 
in adults (Kaufmann, 2000). The reasons why the efficiency of BCG is variable are not fully 
understood, yet one possibility is that the immune responses triggered by BCG and 
M.tuberculosis might be different and so full protection is not achieved by vaccination. However, 
various experimental vaccines developed in recent years and tested in animal models proved to 
be less effective than BCG (Aagaard et al., 2009). This raises the issue that vaccine improvement 
needs to take into consideration the mechanism(s) of protection conferred by BCG and not only 
the immune response triggered by M. tuberculosis. Based on this rational, we proposed to 
compar the responses triggered by M. tuberculosis and BCG at various levels. 
We started by comparing the cytokine responses of bone marrow derived macrophages 
and DCs to live M. tuberculosis or BCG. Our data showed that M. tuberculosis is a stronger 
trigger to DCs than BCG, while the macrophage responses to these two mycobacteria were 
similar (Fig.1 and 2).  
Since cytokine production by DCs is central in the context of Th cell responses, we became 
particullary interested in the induction of cytokines that dictate Th cell differentiation and survival. 
In this this regard, we showed that DCs exposed to M. tuberculosis were induced to expressed 
high amounts of p40 and p19 monomers and of the respective bioactive molecules- IL-12 and IL-
23, whereas BCG appeared to induce a “sub-optimal” stimulation of DCs with very little 
production of these cytokines. The observation that M. tuberculosis-infected DCs produce more 
IL-12p70 than BCG-infected DCs is in agreement with a recent study performed with human DCs 
(Giacomini et al., 2009). In contrast, IL-6 production by M. tuberculosis- or BCG-stimulated DCs 
was similar, and TNF secretion by DCs was higher with the BCG stimulus. Our data therefore 
suggest that distinct molecular pathways must be activated by M. tuberculosis and BCG in DCs 
(Fig.1 and Fig.2). Furthermore, we provide experimental evidence that M. tuberculosis and BCG 
stimulate macrophages and DCs differently, with distinct outcomes. Thus, why are macrophages 
and DCs responding differently to M. tuberculosis or BCG? Macrophages and DCs respond to 
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pathogen-derived products with the induction and production of effector molecules that regulate 
innate and adaptive immune responses (Akira, 2006; Beutler, 2004; Medzhitov, 2001). TLRs are 
within the PPRs that sense mycobacteria (Akira et al., 2006), leading to cytokine production. 
Data from our laboratory suggest that the main TLR involved in the recognition of M. tuberculosis 
and BCG by macrophages and DCs is TLR2. Therefore, the differences observed in terms of 
cytokine expression by DCs and macrophages in response to these mycobacteria is most likely 
not associated to a differential TLR recognition. TLR stimulation induces activation of MAPK such 
as ERK1/2 (Akira and Takeda, 2004). The signalling cascade involving ERK1/2 activation has 
been described before to be involved in the regulation of p40 and p19 gene expression 
(Goodridge et al., 2003; Jang et al., 2009; Kaiser et al., 2009; Saito et al., 2006). Since the 
differences we observed were precisely on the expression of these molecules, we decided to 
investigate a possible difference in terms of ERK1/2 activation. We report here that a differential 
activation of ERK1/2 is in place macrophages versus DCs stimulated with M. tuberculosis or 
BCG (Fig.3). Our data show that an earlier and stronger ERK phosphorylation occurs in 
macrophages stimulated with M. tuberculosis. In macrophages stimulated with BCG, the kinetics 
of ERK phosphorylation was similar to that observed in M. tuberculosis-stimulated macrophages, 
yet this activation was weaker. Additionally, a poor induction of ERK phosphorylation in DCs 
stimulated with BCG was observed in contrast to the other conditions. These results support our 
hypothesis that BCG induces a “sub-optimal” stimulation of macrophages and DCs and suggests 
the ERK1/2 pathway to be involved in this differential activation of DCs by M. tuberculosis versus 
BCG. Furthermore, we also found that ERK1/2 activation was different in macrophages versus 
DCs, stimulated with M. tuberculosis, being this stimulus in macrophages the strongest inducer 
of this cascade. Below, we propose a model (Fig.9) where the threshold of ERK1/2 appears to be 
an important regulatory mechanism for IL-12 and IL-23 induction when macrophages and DCs 
sense M. tuberculosis or BCG, although other mechanisms certainly also exist. Recently Kaiser et 
al. reported that TLR4 and TLR9 activation of ERK1/2 positively regulates IL-10 induction in 
myeloid macrophages and myeloid DCs, in contrast to its negative effects on IL-12 and IFN- 
production (Kaiser et al., 2009). This work is in line with ours, suggesting that ERK1/2 signalling 
is interpreted differently by macrophages and DCs, and this might explain the different amounts 
of cytokine expression.  
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Figure 9 – Levels of ERK 1/2 phosphorylation induced by M. tuberculosis or BCG dictate the 
differential cytokines production by macrophages and DCs. 
 
We now intend to investigate the molecular determinants that might explain the differential 
ERK activation by M. tuberculosis and BCG. We are also interested in determining whether the 
induction of other MAPKs is also differently activated in DCs, by M. tuberculosis or by BCG, and 
whether it contributes to explain differences in terms of cytokine expression. We will also use 
specific MAPK inhibitors to target the putatively differential signalling pathways. The differences in 
p40 and p19 expression will be further investigated at the molecular level, by including studies 
on cytokine gene regulation. The expression of transcription factors involved in the regulation of 
p40 and p19 genes, as well as their nuclear localization and function, will be addressed to find 
out whether M. tuberculosis or BCG lead to differential expression and/or function of 
transcription factors that ultimately explain the differences observed in cytokine responses. One 
transcription factor that has been proposed to be involved in differential stimulation of human 
DCs by M. tuberculosis or BCG is IRF-3 (Giacomini et al., 2009). This transcription factor was 
recently described to be activated upon M. tuberculosis infection, but not upon BCG infection of 
human DCs (Giacomini et al., 2009). It will be interesting to investigate if this is also happening 
in our system. Importantly, the molecular determinants that dictate the differential response of 
DCs to M. tuberculosis or to BCG might be associated with intrinsic properties of these 
mycobacteria. Zenero and collegues, have recently proposed that M. tuberculosis interacts with 
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selected receptors to subvert DCs maturation or change the pattern of DCs cytokine secretion 
(Zenaro et al., 2009). This issue will also be addressed in future experiments. 
Since M. tuberculosis or BCG stimulation of DCs induced a differential expression pattern 
of IL-12 and IL-23 (Fig.1 and Fig.2), and taking into consideration the role of IL-12 (p40-p35) and 
IL-23 (p40-p19) molecules in Th1 differentiation and Th17 survival, respectively, our next goal 
was to determine the consequences of the differential activation of DCs by M. tuberculosis and 
BCG in CD4+ T cell differentiation. We found that this differential activation of DCs was reflected 
on the distinct balance of Th responses developed when M.tuberculosis- or BCG-infected DCs 
presented OVA peptide to TCR-transgenic CD4+ T cells (Fig.4). M.tuberculosis–infected DCs were 
able to induce the development of both Th1 and Th17 responses, which is in agreement with the 
secretion of IL-12, IL-23 and IL-6 by M. tuberculosis-stimulated DCs. On the other hand, we 
observed an unbalanced Th1/Th17 response differentiated in the presence of BCG-infected DCs. 
Indeed, BCG-infected DCs were able to induce a strong Th17 response, but only a limited Th1 
response. We propose that the fact that BCG stimulation of DCs induced an amount of IL-6 
similar to that induced by M. tuberculosis allows for the initiation of Th17 differentiation (Fig.1 
and 2). It is surprising however that the strong Th17 response induced by BCG-infected DCs was 
not accompanied by the secretion of high levels of IL-23. However we only measured the 
production of this cytokine 24 hours post-infection and it is possible that IL-23 accumulates over 
time. Thus it is in our plans to measure IL-23 in supernatants of BCG-infected DCs during an 
extended period of time. It is also possible that the initial diminished IL-12 levels observed in 
BCG-infected DC, compromise Th1 differentiation, allowing for Th17 development. To test this 
hypothesis, we will perform the same assay, but we will exogenously provide IL-12 to the BCG-
infected cultures, in order to see if the Th1/Th17 imbalance can be reverted. Additionally, several 
studies have shown that other cytokines play important roles in Th17 differentiation. This is the 
case of IL-21 (Fantini et al., 2007; Korn et al., 2007; Nurieva et al., 2007; Wei et al., 2007; Zhou 
et al., 2007) and IL-1 (Weaver et al., 2007). In vitro culture of naive CD4+ T cells in the 
presence of IL-21 and TGF- has shown to induced IL-17 production at levels similar to that 
induced by TGF- and IL-6 (Fantini et al., 2007; Korn et al., 2007; Nurieva et al., 2007; Wei et 
al., 2007; Zhou et al., 2007). Moreover, it was demonstrated that Th17 development was 
impaired in the absence of IL-21 signalling (Fantini et al., 2007; Korn et al., 2007; Nurieva et al., 
2007; Wei et al., 2007; Zhou et al., 2007), and that in IL-21-deficient splenocytes, Th17 
development in vitro and in vivo was almost completely abolished (Nurieva et al., 2007). 
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Similarly, a 2- to 3-fold reduction in IL-17 production was observed when purified CD4+ T cells 
were cultured under Th17-inducing conditions in the presence of neutralizing anti-IL-21 antibody 
(Wei et al., 2007). It was also reported that IL-1 and IL-6 in conjunction with TGF- were 
efficient inducers of Th17 differentiation from naive CD4+ T cell precursors (Weaver et al., 2007). 
Therefore, monitoring the expression of IL-21 and IL-1 induced by M. tuberculosis and BCG will 
be also addressed in our future experiments. As for TGF-, our preliminary data suggest that very 
low levels of this cytokine are being produced by DCs in response to M. tuberculosis and BCG. It 
is also important to refer that it is unlikely that suppressive effects mediated by IL-10 account for 
the differences observed, as the levels of this cytokine detected upon stimulation of DCs with M. 
tuberculosis or BCG were similar. Finally, another possible explanation for the Th17 shift 
observed in BCG-stimulated DCs relies on a differential induction of co-stimulatory molecules 
expressed by DCs. This will be addressed by measuring the presence of the main co-stimulatory 
molecules in M. tuberculosis- versus BCG-infected DC by flow cytometry. This hypothesis is in 
line with a recent study showing that BCG is less efficient in inducing human DCs maturation 
than M. tuberculosis (Giacomini et al., 2009). 
Our in vitro studies on Th cell differentiation in response to M. tuberculosis or BCG were 
further explored in vivo (Fig4. and Fig.5). We showed that, for the time points tested, a higher 
number of IFN--producing CD4+ T cells developed in M. tuberculosis-infected animals than in 
BCG-infected ones. The peak of IL-17-producing CD4+ T cells for M. tuberculosis-infected animals 
(day7) appeared to occur earlier than for BCG-infected animals. However soon after that peak, 
Th17 induced by BCG rose sharply. We are now interested in addressing weather these 
differences are maintained over the time and whether they might be related to different bacterial 
load in BCG- or M. tuberculosis-infected animals. These questions will be addressed in future 
experiments. Below, we propose a model (Fig.10) for IFN- and IL-17 -producing CD4+ T cells 
developed by M. tuberculosis and BCG infections, with possible factors that might explain the 
observed differences. 
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Figure 10 – Balance of Th cell differentiation in response to M. tuberculosis or BCG. 
 
Our findings might be important for the understanding of the development of the immune 
response to BCG as compared to that of M. tuberculosis. Our findings suggest that BCG induces 
the development of an effective Th17 response that does not appear to be fully controlled by Th1 
cells, which might be important for the protection achieved by this vaccine. This is in line with a 
previous report showing that Th17 responses are needed to achieve protection against TB, due to 
their role in recruiting Th1 cells to the site of infection (Khader et al., 2007). On the other hand, it 
has been suggested that increased Th1 responses or IFN- production are not necessarily 
needed to achieve high protection against TB (Jeevan et al., 2009). Therefore, our data is in 
agreement with the idea that the development of new vaccines to TB should consider the 
improvement of Th17 responses in an initial phase, and not only a very potent IFN- production. 
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As part of this work, we have also compared the macrophage response to M. tuberculosis 
or BCG. Although the cytokine expression pattern was similar in macrophages stimulated with M. 
tuberculosis or BCG (Fig.1), it appeared that BCG presented a delayed growth (day 2 post 
infection) in macrophages when compared to M. tuberculosis. To further clarify if the anti-
mycobacterial activity of macrophages was more effective, at this time point, against BCG than 
against M. tuberculosis, we started by measuring NO production (a fast and earlier bactericidal 
mechanism) by BCG- or M. tuberculosis-infected macrophages. Here we showed that NO 
production most likely was not the effector mechanism behind the protection observed on BCG-
infected macrophages at 2 days post-infection (Fig.6). Nonetheless, other bactericidal 
mechanisms of macrophages might account for the differential protection observed, such as 
H2O2/O- 2, defensines, lysosomal hydrolases, chemokines, and phagosome-lysosoma fusion. The 
expression of several markers that follows phagosome maturation and phagosome-lysosome 
fusion, including tryptophan-aspartate containing coat protein (TACO), lysosomal-associated 
membrane protein (LAMP-1) and LRG-47 (Fol et al., 2006; Pieters, 2001) will be targets of 
further studies. 
We also questioned whether the observed differences could be related to a distinct 
induction a apoptosis. Apoptosis of cells infected with intracellular pathogens may benefit the 
host by eliminating a supportive environment for bacterial growth. Members of the caspase family 
are central to initiation and execution of apoptosis and caspase-3 is one of the main forms 
activated during this pathway (Lee et al., 2009b). Our results show that M. tuberculosis induced 
high rates of caspase-3-mediated apoptosis in macrophages at early time points post-infection, 
reaching its maximum 2 days post-infection, while in BCG infection a significantly increase of 
caspase-3 positive cells was observed over the time of infection. Despite the existence of more 
cells undergoing apoptosis at 2 days post infection in the infection by M. tuberculosis, the 
bacterial burden was higher for this bacterium. This might mean that at this time point, M. 
tuberculosis is already able to survive and replicate within macrophages, thus suggesting that the 
type of apoptosis induced by M. tuberculosis early on infection is not associated with a protective 
response. However, Keane et al reported that the attenuated M. tuberculosis strain H37Ra was a 
more potent inducer of apoptosis than the virulent strain H37Rv (Keane et al., 1997). These 
authors proposed that bacillary control of the host cell apoptosis is a virulence-associated 
phenotype of M. tuberculosis strains and suggested that alveolar macrophages apoptosis 
contributes to innate immunity in TB (Keane et al., 1997). In a way, our results point to the 
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opposite idea, since in our study, the avirulent strain (BCG) was a slower inducer of apoptosis. 
We nonetheless must take into account the technical differences between the two works, such as 
the type of cells (alveolar versus bone marrow-derived macrophages), the bacterial strains 
(H37Ra versus BCG)and the doses of mycobacteria used (MOI of 5 versus MOI of 2), as well as 
the assessment of apoptosis (DNA fragmentation versus caspase-3). Future studies are required 
to clarify the differences observed in terms of M. tuberculosis or BCG growth within the infected 
macrophage. 
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VI. CONCLUSIONS 
 
In this work we were able to show that macrophages and DC respond differently to M. 
tuberculosis or BCG stimulation, and this might be due in part to a differential activation of ERK 
1/2 induced by M. tuberculosis or BCG. A consequence of this differential activation of DC was 
reflected on the distinct type of Th responses developed, both in vitro and in vivo. The effector 
activity of macrophages in what regards the control of M. tuberculosis or BCG growth was also 
different, although the differences found were not due to differential NO production or apoptosis. 
 
A detailed comparative study of BCG versus M. tuberculosis infection on macrophages and 
DC might provide insights on how these mycobacteria interact with the immune system and how 
that translates into an effective, or not, Th cell response and also the mechanisms used by the 
pathogen to modulate the immune response. Furthermore, dissecting the cellular and molecular 
events that occur upon mycobacterial challenge will help to reveal possible weak points of both 
the host and the bacteria that can be targeted from a prophylactic point of view. 
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